Checkpoint Inhibitors
Home > Catalog Peptides > Checkpoint Inhibitors

If you find Creative Peptides is useful to satisfy your needs, please do not hesitate to contact us!

Checkpoint Inhibitors

Browse products name by alphabetical order:

Cat. # Product Name Price
CR00002 HIV-1 gag Protein p17 (76-84) Inquiry
CR00001 CBP501 Affinity Peptide Inquiry
O1703 Ovalbumin (323-339) (chicken, japanese quail) Inquiry
C33011 Cytochrome C (88-104) (domestic pigeon) Inquiry
C14019 CEF20, Cytomegalovirus, CMV pp65 (495-503) Inquiry
C14001 CEF1, Influenza Matrix Protein M1 (58-66) Inquiry

An important part of the immune system is its ability to distinguish between normal cells in the body and cells that it considers to be “foreign”. This allows the immune system to attack foreign cells away from normal cells. To do this, it uses “checkpoints”-some molecules on immune cells that need to be activated (or inactivated) to initiate an immune response. Checkpoint inhibitors are also described as a monoclonal antibody or targeted therapy.

Examples of Checkpoint Inhibitors

  1. PD-1 or PD-L1 inhibitors
  2. PD-1 is a checkpoint protein on immune cells called T cells. It usually acts as a “shutdown switch” to help prevent T cells from attacking other cells in the body. It does this when it attaches to PD-L1, a protein on some normal and cancer cells. When PD-1 binds to PD-L1, it basically tells T cells to stay away from another cell. Some cancer cells contain large amounts of PD-L1, which helps them escape immune attacks. Monoclonal antibodies against PD-1 or PD-L1 can block this binding and enhance the immune response to cancer cells. These drugs show great potential in the treatment of certain cancers.

  3. CTLA-4 inhibitors
  4. CTLA-4 is another protein on some T cells that acts as a “shutdown switch” to maintain control of the immune system. CTLA-4 can suspend the response of activated T cells to (T cell response) and mediate the inhibitory function of Treg. Using a mouse model of bladder cancer, the researchers found that local injection of low doses of anti-CTLA-4 antibody into the tumor area had the same ability to inhibit the tumor as it did when the antibody was transported in the blood. At the same time, the level of circulating antibody is also low, that is, the effect of local injection of anti-CTLA-4 is the same as that of anti-CTLA-4 antibody injected in blood. At the same time, the level of antibody in circulation is also low, suggesting that local application of anti-CTLA-4 treatment can reduce adverse reactions.

Conclusion

The clinical success of immunosuppressive agents has brought new life to the immunotherapy of cancer. What we need to do in the future is how to improve the efficiency of immune checkpoint blocking and immune checkpoint inhibitor combination therapy to enable patients who cannot be treated with single blocker to obtain a lasting anti-tumor response. How to develop an effective combination of immune checkpoint blocking therapy to increase efficacy and reduce side effects. Tumors use a variety of means to escape immune elimination, so it is necessary to better understand the immunosuppression of tumor microenvironment.

References
1. Mahoney, K. M., Freeman, G. J., & McDermott, D. F. (2015). The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clinical therapeutics37(4), 764-782.
2. Hui, E. (2019). Immune checkpoint inhibitors. J Cell Biol218(3), 740-741.

If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.

Useful Tools

Peptide Calculator

Abbreviation List

Peptide Glossary

Follow us on:

Copyright © 2008 - Creative Peptides. All rights reserved.

USA

Address: 45-16 Ramsey Road, Shirley, NY 11967, USA

Tel: 1-631-624-4882

Fax: 1-631-614-7828

E-Mail:

Europe

Tel: 44-207-097-1828

E-Mail: